Rivastigmine for the treatment of dementia associated with Parkinson's disease.

Hdl Handle:
http://hdl.handle.net/10675.2/139
Title:
Rivastigmine for the treatment of dementia associated with Parkinson's disease.
Authors:
Reingold, Jennifer L; Morgan, John C; Sethi, Kapil D
Abstract:
Parkinson's disease (PD) afflicts millions of people worldwide and leads to cognitive impairment or dementia in the majority of patients over time. Parkinson's disease dementia (PDD) is characterized by deficits in attention, executive and visuospatial function, and memory. The clinical diagnostic criteria and neuropathology surrounding PDD remain controversial with evidence of overlap among PDD, dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Cortical cholinergic deficits are greater in PDD than in AD, and are well-correlated with the cognitive and neuropsychiatric dysfunction that occurs in PDD. Inhibition of acetylcholine metabolism is therefore a practical therapeutic strategy in PDD.This review examines current evidence for rivastigmine (a cholinesterase/butyrylcholinesterase inhibitor) treatment in PDD. In addition to its efficacy, we examine the safety profile, side effects, and cost effectiveness of rivastigmine in PDD. Rivastigmine provides modest benefit in PDD and further long-term studies are needed to determine the effectiveness and safety of rivastigmine over time. Tolerability is a problem for many PDD patients treated with rivastigmine. Future studies of rivastigmine in PDD should focus on pragmatic outcomes such as time to need for nursing home placement, pharmacoeconomic outcomes and simultaneous patient/caregiver quality of life assessments.
Citation:
Neuropsychiatr Dis Treat. 2007 Dec; 3(6):775-783
Issue Date:
20-Mar-2009
URI:
http://hdl.handle.net/10675.2/139
PubMed ID:
19300613
PubMed Central ID:
PMC2656320
Type:
Journal Article
ISSN:
1176-6328
Appears in Collections:
Department of Neurology: Faculty Research and Presentations

Full metadata record

DC FieldValue Language
dc.contributor.authorReingold, Jennifer Len_US
dc.contributor.authorMorgan, John Cen_US
dc.contributor.authorSethi, Kapil Den_US
dc.date.accessioned2010-09-24T22:03:26Z-
dc.date.available2010-09-24T22:03:26Z-
dc.date.issued2009-03-20en_US
dc.identifier.citationNeuropsychiatr Dis Treat. 2007 Dec; 3(6):775-783en_US
dc.identifier.issn1176-6328en_US
dc.identifier.pmid19300613en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/139-
dc.description.abstractParkinson's disease (PD) afflicts millions of people worldwide and leads to cognitive impairment or dementia in the majority of patients over time. Parkinson's disease dementia (PDD) is characterized by deficits in attention, executive and visuospatial function, and memory. The clinical diagnostic criteria and neuropathology surrounding PDD remain controversial with evidence of overlap among PDD, dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Cortical cholinergic deficits are greater in PDD than in AD, and are well-correlated with the cognitive and neuropsychiatric dysfunction that occurs in PDD. Inhibition of acetylcholine metabolism is therefore a practical therapeutic strategy in PDD.This review examines current evidence for rivastigmine (a cholinesterase/butyrylcholinesterase inhibitor) treatment in PDD. In addition to its efficacy, we examine the safety profile, side effects, and cost effectiveness of rivastigmine in PDD. Rivastigmine provides modest benefit in PDD and further long-term studies are needed to determine the effectiveness and safety of rivastigmine over time. Tolerability is a problem for many PDD patients treated with rivastigmine. Future studies of rivastigmine in PDD should focus on pragmatic outcomes such as time to need for nursing home placement, pharmacoeconomic outcomes and simultaneous patient/caregiver quality of life assessments.en_US
dc.rightsThe PMC Open Access Subset is a relatively small part of the total collection of articles in PMC. Articles in the PMC Open Access Subset are still protected by copyright, but are made available under a Creative Commons or similar license that generally allows more liberal redistribution and reuse than a traditional copyrighted work. Please refer to the license statement in each article for specific terms of use. The license terms are not identical for all articles in this subset.en_US
dc.titleRivastigmine for the treatment of dementia associated with Parkinson's disease.en_US
dc.typeJournal Articleen_US
dc.identifier.pmcidPMC2656320en_US
dc.contributor.corporatenameDepartment of Neurologyen_US

Related articles on PubMed

All Items in Scholarly Commons are protected by copyright, with all rights reserved, unless otherwise indicated.